Cardiovascular disease is a major cause of morbidity and mortality worldwide.

The term encompasses several conditions, including coronary artery disease, myocardial infarction, hypertension, heart failure, cardiomyopathies, arrhythmias, and cerebrovascular disease.

Traditional cardiovascular risk factors include elevated blood pressure, abnormal lipid levels, diabetes, obesity, smoking, poor dietary patterns, and physical inactivity.

However, individuals with similar environmental exposures can develop markedly different cardiovascular outcomes.

This variation indicates that genetic susceptibility contributes to disease development.

Family and twin studies have demonstrated that many cardiovascular traits have a substantial heritable component.

Advances in molecular genetics have subsequently identified numerous genetic variants associated with cardiovascular phenotypes.

These variants may influence lipid metabolism, vascular tone, inflammation, thrombosis, myocardial contractility, and cardiac electrical activity.

Understanding these genetic mechanisms can improve knowledge of cardiovascular pathophysiology and may contribute to more individualized approaches to prevention and treatment.

Genetic Architecture of Cardiovascular Disease

Genetic contributions to cardiovascular disease can involve common variants with relatively small effects or rare variants with much larger effects.

Common single-nucleotide polymorphisms may slightly alter the probability of developing coronary artery disease.

In contrast, pathogenic variants in genes responsible for familial hypercholesterolemia or inherited cardiomyopathies can substantially increase disease risk.

Genetic effects can also operate through intermediate phenotypes.

For example, a variant may increase LDL cholesterol, which subsequently increases the risk of atherosclerosis.

Other variants directly affect myocardial structure or cardiac ion channels and may predispose individuals to arrhythmias.

Major Genes and Genetic Variations

Genetic Variations in Lipid Metabolism

Abnormal lipid levels are among the strongest modifiable risk factors for atherosclerotic cardiovascular disease.

Genetic variation can influence circulating concentrations of LDL cholesterol, HDL cholesterol, triglycerides, and lipoprotein(a).

The LDLR gene encodes the low-density lipoprotein receptor responsible for removing LDL particles from circulation.

Pathogenic variants in LDLR can reduce receptor function and cause familial hypercholesterolemia.

APOB encodes apolipoprotein B, a major structural component of atherogenic lipoproteins.

Variants affecting APOB can alter LDL metabolism and contribute to hypercholesterolemia.

PCSK9 regulates LDL receptor degradation.

Gain-of-function variants can increase LDL cholesterol, whereas certain loss-of-function variants can reduce LDL cholesterol and cardiovascular risk.

These findings have also contributed to the development of PCSK9-targeted therapies.

Lipoprotein(a) and Genetic Cardiovascular Risk

Lipoprotein(a) is an LDL-like particle associated with atherosclerotic cardiovascular disease and calcific aortic valve disease.

Its concentration is strongly influenced by genetic variation in the LPA gene.

Unlike many conventional cardiovascular risk factors, lipoprotein(a) levels are relatively stable throughout life.

High genetically determined Lp(a) concentrations can contribute to increased cardiovascular risk.

The LPA locus therefore represents an important example of how genetic variation can influence an intermediate cardiovascular phenotype.

Genetic Susceptibility to Hypertension

Blood pressure is influenced by numerous genetic and environmental factors.

Genes involved in the renin–angiotensin–aldosterone system have been extensively investigated.

ACE participates in the conversion of angiotensin I to angiotensin II.

AGT encodes angiotensinogen, a precursor of angiotensin peptides.

Genetic variation within these pathways may influence vascular tone, sodium balance, and blood pressure.

However, hypertension is highly polygenic, and individual variants generally exert relatively small effects.

Dietary sodium intake, obesity, physical activity, age, and kidney function can substantially modify genetic susceptibility.

Endothelial Function and NOS3

Endothelial cells regulate vascular tone through the production of signaling molecules including nitric oxide.

NOS3 encodes endothelial nitric oxide synthase, an enzyme responsible for nitric oxide production in vascular endothelial cells.

Certain NOS3 variants have been investigated in relation to endothelial dysfunction, hypertension, and coronary artery disease.

Reduced nitric oxide bioavailability can contribute to impaired vasodilation, inflammation, and vascular dysfunction.

These processes are central to the development of atherosclerosis.

Genetic Variations and Coronary Artery Disease

Coronary artery disease is a complex disorder resulting from interactions between lipid accumulation, inflammation, endothelial dysfunction, thrombosis, and vascular remodeling.

Large-scale genome-wide association studies have identified numerous loci associated with coronary artery disease.

Some variants influence LDL cholesterol and other established risk factors.

Other variants appear to affect vascular inflammation and arterial-wall biology independently of conventional risk factors.

The 9p21 chromosomal region is one of the most extensively studied genetic loci associated with coronary artery disease.

The biological mechanisms linking this region to atherosclerosis involve regulation of vascular-cell proliferation and extracellular matrix biology.

Genetic Factors in Cardiomyopathies

Unlike common coronary artery disease, some cardiomyopathies have strong monogenic components.

Hypertrophic cardiomyopathy is frequently associated with pathogenic variants affecting sarcomere proteins.

MYH7 and MYBPC3 are among the most extensively studied genes.

Variants in these genes can alter sarcomere structure and cardiac contractility.

Dilated cardiomyopathy can also result from pathogenic variants in multiple genes.

LMNA variants are associated with cardiomyopathy, conduction abnormalities, and arrhythmias.

Genetic testing can therefore be particularly valuable in patients with suspected inherited cardiomyopathy and in appropriate family members.

Genetic Variations and Cardiac Arrhythmias

Cardiac rhythm depends on coordinated electrical activity involving ion channels and conduction pathways.

Genetic variation affecting ion-channel proteins can alter cardiac action potentials.

SCN5A encodes a major cardiac sodium channel and is associated with several inherited arrhythmia syndromes.

KCNQ1 encodes a potassium-channel component involved in cardiac repolarization.

Pathogenic variants can predispose individuals to long QT syndrome and other rhythm disorders.

These inherited conditions demonstrate how genetic changes can directly influence cardiac electrophysiology.

Figure 1. Genetic Pathways Contributing to Cardiovascular Disease

                     GENETIC VARIATION

                            │

       ┌────────────────────┼────────────────────┐

       ▼                    ▼                    ▼

   Lipid Genes          Vascular Genes       Cardiac Genes

       │                    │                    │

       ▼                    ▼                    ▼

 LDLR / APOB / PCSK9    ACE / AGT / NOS3    MYH7 / SCN5A / KCNQ1

       │                    │                    │

       ▼                    ▼                    ▼

 LDL & Lp(a)           Blood Pressure      Contractility /

       │                & Endothelium        Electrical Activity

       │                    │                    │

       └────────────────────┼────────────────────┘

                            ▼

                  Cardiovascular Susceptibility

                            │

              ┌─────────────┴─────────────┐

              ▼                           ▼

        Atherosclerosis             Cardiac Disease

              │                           │

              ▼                           ▼

       Coronary Artery Disease      Arrhythmia /

                                    Cardiomyopathy

Figure 1: Simplified representation of genetic pathways through which variations in lipid metabolism, vascular regulation, and cardiac structure or electrical activity may contribute to cardiovascular disease susceptibility.

Genetic Risk Scores

Because common cardiovascular disease is polygenic, individual variants generally provide limited predictive information.

Polygenic risk scores combine information from multiple genetic variants to estimate inherited susceptibility.

A high polygenic risk score may identify individuals who have increased inherited risk even when conventional risk factors are not markedly elevated.

However, genetic risk should be interpreted alongside established clinical factors.

A genetic predisposition does not guarantee disease development, and favorable lifestyle factors can modify overall risk.

Gene–Environment Interactions

Cardiovascular disease develops through interactions between inherited susceptibility and environmental exposure.

Smoking, obesity, physical inactivity, poor dietary patterns, hypertension, diabetes, and abnormal lipid levels can increase disease risk.

Genetic variants may influence how strongly individuals respond to these exposures.

For example, variants affecting lipid metabolism may become more clinically important in the presence of diets associated with elevated LDL cholesterol.

Similarly, genetic susceptibility to hypertension may interact with dietary sodium intake and body weight.

Understanding these interactions may improve prevention strategies.

Review Design

The present article was prepared as a narrative review examining genetic variations associated with cardiovascular disease susceptibility.

Literature Search

Relevant scientific literature was considered from major biomedical databases and peer-reviewed journals.

Search terms included combinations of “cardiovascular disease,” “genetic variation,” “genetic polymorphism,” “coronary artery disease,” “familial hypercholesterolemia,” “LDLR,” “APOB,” “PCSK9,” “LPA,” “hypertension genetics,” “cardiomyopathy,” and “cardiac arrhythmia.”

Inclusion Criteria

Studies addressing genetic variants associated with cardiovascular disease, lipid metabolism, blood pressure, vascular biology, cardiomyopathy, arrhythmias, or cardiovascular risk prediction were considered relevant.

Data Synthesis

The evidence was organized according to genetic mechanisms, lipid metabolism, vascular regulation, cardiac structural disorders, arrhythmias, gene–environment interactions, and potential applications in precision cardiovascular medicine.

Results

The reviewed evidence indicates that genetic variation contributes to cardiovascular disease through multiple biological pathways.

Variants in LDLR, APOB, PCSK9, and LPA influence lipid metabolism and atherosclerotic risk.

Genes involved in the renin–angiotensin system and endothelial nitric oxide signaling may influence blood pressure and vascular function.

Rare pathogenic variants in genes such as MYH7, MYBPC3, and LMNA can contribute substantially to inherited cardiomyopathies.

Variants in SCN5A and KCNQ1 can affect cardiac electrical activity and predispose individuals to inherited arrhythmias.

Overall, the genetic contribution to cardiovascular disease ranges from small effects associated with common variants to large effects associated with rare pathogenic variants.

Genetic variation provides an important explanation for differences in cardiovascular disease susceptibility among individuals.

One of the clearest examples is familial hypercholesterolemia.

Pathogenic variants affecting LDLR, APOB, or PCSK9 can produce markedly elevated LDL cholesterol from an early age.

Persistent exposure to high LDL concentrations can accelerate atherosclerotic plaque development.

These inherited disorders demonstrate how a genetic alteration can influence cardiovascular disease through a measurable intermediate phenotype.

Lipoprotein(a) provides another important example.

LPA-associated variation can produce substantial differences in circulating Lp(a) concentrations.

Because Lp(a) is an independent risk factor for atherosclerotic disease, genetic variation in LPA can contribute to cardiovascular susceptibility.

In contrast, common coronary artery disease is highly polygenic.

Numerous variants contribute small increments of risk.

This means that genetic testing based on a single polymorphism generally has limited predictive value for common cardiovascular disease.

Polygenic risk scores may provide a broader estimate by integrating information from many variants.

However, their predictive performance can vary across populations.

Inherited cardiomyopathies and arrhythmias represent a different genetic model.

A single pathogenic variant can sometimes have a substantial effect on disease risk.

In these conditions, genetic testing can have direct implications for diagnosis, family screening, and clinical management.

Genetic information can also influence treatment strategies.

The discovery of PCSK9 as a regulator of LDL receptor activity contributed to the development of PCSK9-targeted therapies.

This illustrates how genetic research can identify biological pathways that become therapeutic targets.

The clinical value of cardiovascular genetics therefore extends beyond risk prediction.

Genomic information can improve disease classification, identify inherited conditions, guide family screening, and contribute to therapeutic development.

Genetic Variations and Personalized Cardiovascular Medicine

Genomic information may become increasingly integrated with conventional cardiovascular risk assessment.

A future precision-medicine model could combine genetic data with blood pressure, lipid levels, imaging, metabolic markers, lifestyle, and family history.

Limitations and Challenges

Several limitations affect the clinical implementation of cardiovascular genetics.

First, most common cardiovascular traits are polygenic.

The effect of individual variants is often small.

Second, genetic associations may differ among populations because allele frequencies and genetic backgrounds vary.

Third, many genetic loci identified through genome-wide association studies are located in non-coding regions, making their biological mechanisms difficult to determine.

Fourth, genetic information does not replace established cardiovascular risk factors.

Finally, genetic testing requires appropriate counseling and interpretation to prevent misunderstanding of risk.

Future Perspectives

Future cardiovascular genetics research will increasingly focus on multi-omics approaches.

Genomics can be integrated with transcriptomics, proteomics, metabolomics, and epigenomics to better understand disease mechanisms.

Large multi-ancestry studies will be essential for improving the accuracy and equity of genetic risk prediction.

Single-cell technologies may help identify how genetic variants influence specific vascular or cardiac cell populations.

Artificial intelligence may also assist in integrating genomic information with clinical and imaging data.

In inherited cardiovascular diseases, genomic screening may allow earlier identification of individuals at risk before symptoms develop.

Such approaches could facilitate earlier intervention and family-based prevention.

Genetic variations contribute substantially to susceptibility to cardiovascular disease through diverse molecular pathways.

Variants affecting LDLR, APOB, PCSK9, and LPA can influence lipid metabolism and atherosclerotic risk, while genetic variation in ACE, AGT, and NOS3 can influence vascular regulation.

Pathogenic variants in MYH7, MYBPC3, LMNA, SCN5A, and KCNQ1 are important causes of inherited cardiomyopathies and arrhythmias.

The genetic architecture of cardiovascular disease ranges from highly penetrant variants causing inherited disorders to numerous common variants producing modest changes in risk.

Future integration of genetic information with conventional risk factors, molecular biomarkers, imaging, and lifestyle characteristics may strengthen personalized cardiovascular prevention.

A better understanding of genetic susceptibility may ultimately support earlier diagnosis, improved risk stratification, family screening, and more individualized therapeutic strategies.

1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140:e596–e646.
2. Nelson CP, Goel A, Butterworth AS, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nature Genetics. 2017;49:1385–1391.
3. van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circulation Research. 2018;122:433–443.
4. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics. 2018;50:1219–1224.
5. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148:1242–1257.
6. Nelson CP, Samani NJ. A review of the role of genetic variation in coronary artery disease. Current Opinion in Cardiology. 2013;28:251–258.
7. Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future prospects. Nature Reviews Cancer. 2017;17:692–704.
8. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics. 2003;34:154–156.
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47.
10. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal. 2010;31:2844–2853.
11. Kronenberg F. Human genetics and the causal role of lipoprotein(a) for atherothrombotic disease. Cardiovascular Research. 2014;102:363–372.
12. Chatterjee S, Narang A, Joshi S, et al. Genetic and environmental factors in hypertension. Nature Reviews Cardiology. 2022;19:10–25.
13. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104:557–567.
14. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. Journal of the American College of Cardiology. 2014;64:83–99.
15. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nature Reviews Cardiology. 2013;10:531–547.
16. Schwartz PJ, Ackerman MJ, George AL, Wilde AAM. Impact of genetics on the clinical management of channelopathies. Journal of the American College of Cardiology. 2013;62:169–180.
17. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932–1963.
18. Tada H, Kawashiri MA, Yamagishi M. Clinical perspectives of genetic testing for familial hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2017;24:425–433.
19. Turley TN, O'Brien EC, Tcheandjieu C, et al. Genomic discovery and clinical translation in cardiovascular disease. Circulation. 2020;142:1–15.
20. Musunuru K, Kathiresan S. Genetics of common, complex coronary artery disease. Cell. 2019;177:132–145.